Integra is buying the U.S. rights to Tornier's Salto Talaris and Salto XT ankle replacement products and its Futura silastic toe replacement products for an undisclosed cash payment. The deal is intended to satisfy antitrust concerns in Wright Medical's pending purchase of Tornier and to strengthen Integra's position in the lower-extremity market.
Tornier NV has cleared the way to be purchased by Wright Medical Group NV and Integra LifeSciences Holdings Corp. has strengthened its position in the lower-extremity space in a deal announced Sept. 3.
Integra is buying the U.S. rights to Tornier's Salto Talaris and Salto XT ankle replacement products and its Futura silastic...
Create an account to read this article
Already a subscriber?
The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.
Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.
